247 related articles for article (PubMed ID: 22102708)
1. Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.
Kuriakose E; Vandris K; Wang YL; Chow W; Jones AV; Christos P; Cross NC; Silver RT
Haematologica; 2012 Apr; 97(4):538-42. PubMed ID: 22102708
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
[TBL] [Abstract][Full Text] [Related]
3. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.
Larsen TS; Bjerrum OW; Pallisgaard N; Andersen MT; Møller MB; Hasselbalch HC
Ann Hematol; 2008 Oct; 87(10):847-50. PubMed ID: 18481066
[TBL] [Abstract][Full Text] [Related]
4. [Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].
Bai J; Xue YP; Zhang L; Li CH; Fan DM; Li B; Xu SC; Li DP; Sun XJ; Jiang B; Yang RC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):444-9. PubMed ID: 21518505
[TBL] [Abstract][Full Text] [Related]
5. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC
Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
[TBL] [Abstract][Full Text] [Related]
6. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.
Jones AV; Silver RT; Waghorn K; Curtis C; Kreil S; Zoi K; Hochhaus A; Oscier D; Metzgeroth G; Lengfelder E; Reiter A; Chase AJ; Cross NC
Blood; 2006 Apr; 107(8):3339-41. PubMed ID: 16352805
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
Quintás-Cardama A; Kantarjian H; Manshouri T; Luthra R; Estrov Z; Pierce S; Richie MA; Borthakur G; Konopleva M; Cortes J; Verstovsek S
J Clin Oncol; 2009 Nov; 27(32):5418-24. PubMed ID: 19826111
[TBL] [Abstract][Full Text] [Related]
8. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
[TBL] [Abstract][Full Text] [Related]
9. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy.
Silver RT; Vandris K; Wang YL; Adriano F; Jones AV; Christos PJ; Cross NC
Leuk Res; 2011 Feb; 35(2):177-82. PubMed ID: 20650526
[TBL] [Abstract][Full Text] [Related]
10. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.
Sørensen AL; Mikkelsen SU; Knudsen TA; Bjørn ME; Andersen CL; Bjerrum OW; Brochmann N; Patel DA; Gjerdrum LMR; El Fassi D; Kruse TA; Larsen TS; Mourits-Andersen HT; Nielsen CH; Ellervik C; Pallisgaard N; Thomassen M; Kjær L; Skov V; Hasselbalch HC
Haematologica; 2020 Sep; 105(9):2262-2272. PubMed ID: 33054051
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden.
Zalcberg IR; Ayres-Silva J; de Azevedo AM; Solza C; Daumas A; Bonamino M
Haematologica; 2011 Mar; 96(3):e18-20. PubMed ID: 21357711
[No Abstract] [Full Text] [Related]
13. JAK2V617F allele burden is associated with transformation to myelofibrosis.
Koren-Michowitz M; Landman J; Cohen Y; Rahimi-Levene N; Salomon O; Michael M; Amariglio N; Nagler A
Leuk Lymphoma; 2012 Nov; 53(11):2210-3. PubMed ID: 22524513
[TBL] [Abstract][Full Text] [Related]
14. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.
Kiladjian JJ; Cassinat B; Chevret S; Turlure P; Cambier N; Roussel M; Bellucci S; Grandchamp B; Chomienne C; Fenaux P
Blood; 2008 Oct; 112(8):3065-72. PubMed ID: 18650451
[TBL] [Abstract][Full Text] [Related]
15. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
[TBL] [Abstract][Full Text] [Related]
16. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
17. Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F.
Steimle C; Lehmann U; Temerinac S; Goerttler PS; Kreipe H; Meinhardt G; Heimpel H; Pahl HL
Ann Hematol; 2007 Apr; 86(4):239-44. PubMed ID: 17256145
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.
Antonioli E; Carobbio A; Pieri L; Pancrazzi A; Guglielmelli P; Delaini F; Ponziani V; Bartalucci N; Tozzi L; Bosi A; Rambaldi A; Barbui T; Vannucchi AM
Haematologica; 2010 Aug; 95(8):1435-8. PubMed ID: 20418246
[No Abstract] [Full Text] [Related]
19. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.
Kiladjian JJ; Cassinat B; Turlure P; Cambier N; Roussel M; Bellucci S; Menot ML; Massonnet G; Dutel JL; Ghomari K; Rousselot P; Grange MJ; Chait Y; Vainchenker W; Parquet N; Abdelkader-Aljassem L; Bernard JF; Rain JD; Chevret S; Chomienne C; Fenaux P
Blood; 2006 Sep; 108(6):2037-40. PubMed ID: 16709929
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.
Quintás-Cardama A; Abdel-Wahab O; Manshouri T; Kilpivaara O; Cortes J; Roupie AL; Zhang SJ; Harris D; Estrov Z; Kantarjian H; Levine RL; Verstovsek S
Blood; 2013 Aug; 122(6):893-901. PubMed ID: 23782935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
